The Latest Breaking News from Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The head of the World Health Organization has called on Pfizer to make its COVID-19 treatment more widely available in poorer countries

Unvaccinated pregnant women who catch Covid-19 are more likely to fall seriously ill

"We are excited to announce Pfizer’s proposed acquisition of Biohaven, recognizing the market leadership of Nurtec, our breakthrough all in one migraine therapy," said CEO Vlad Coric.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Pfizer will acquire migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal that sent BHVN stock rocketing.

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion.  Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock.  The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

Levels of antibodies waned in period between third jabs and fourth boosters